(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.61%.
Aligos Therapeutics's earnings in 2026 is -$86,462,000.On average, 6 Wall Street analysts forecast ALGS's earnings for 2026 to be -$44,375,941, with the lowest ALGS earnings forecast at -$52,465,440, and the highest ALGS earnings forecast at -$32,047,855. On average, 5 Wall Street analysts forecast ALGS's earnings for 2027 to be -$42,618,478, with the lowest ALGS earnings forecast at -$58,194,425, and the highest ALGS earnings forecast at -$25,005,080.
In 2028, ALGS is forecast to generate -$6,004,665 in earnings, with the lowest earnings forecast at -$38,655,571 and the highest earnings forecast at $39,930,594.